Loading...
Loading...
Browse all stories on DeepNewz
VisitWhat will be the most commonly negotiated drug category under IRA provisions in 2025?
Insulin • 25%
Cancer medications • 25%
Cardiovascular drugs • 25%
Other • 25%
Data from Medicare or pharmaceutical industry reports
Medicare Part D Enrollees to Benefit from $2,000 Annual Prescription Drug Cost Cap Under Inflation Reduction Act
Dec 31, 2024, 04:30 PM
Starting January 1, 2025, Medicare Part D enrollees will benefit from a new annual cap on out-of-pocket prescription drug costs set at $2,000, as mandated by the Inflation Reduction Act. This cap, which was temporarily set at $3,500 for 2024, aims to provide financial relief to seniors and others on Medicare, particularly those with high medication costs. The Act, passed by Democrats and opposed by all Republicans, also includes other measures such as a $35 monthly cap on insulin prescriptions and provisions allowing Medicare to negotiate drug prices. The change is expected to save millions of Americans money on their medications, with over 3 million Medicare beneficiaries projected to benefit from the $2,000 cap in 2025, rising to over 4 million by 2029.
View original story
Cardiovascular drugs • 25%
Cancer treatments • 25%
Diabetes medications • 25%
Other • 25%
Schizophrenia drugs • 25%
mRNA vaccines • 25%
Other • 25%
TCR-engineered T cell therapies • 25%
Cardiovascular treatment • 25%
Other • 25%
Neurological treatment • 25%
Cancer treatment • 25%
Cardiovascular drugs • 25%
Cancer drugs • 25%
Insulin • 25%
Other • 25%
Novel biologics • 25%
New molecular entities • 25%
Other • 25%
Biparatopic antibodies • 25%
More than 30 drugs • 25%
11-20 drugs • 25%
1-10 drugs • 25%
21-30 drugs • 25%
Chronic condition medications • 25%
Diabetes medications • 25%
Other • 25%
Cancer treatments • 25%
Consumer Goods • 25%
Technology • 25%
Pharmaceuticals • 25%
Healthcare • 25%
Johnson & Johnson • 25%
Pfizer • 25%
Other • 25%
Moderna • 25%
Patients • 25%
Healthcare Providers • 25%
Insurance Companies • 25%
Pharmaceutical Companies • 25%
Ozempic • 25%
Other • 25%
Semaglutide • 25%
Wegovy • 25%
PEPFAR • 25%
Gilead Sciences • 25%
Other • 25%
Global Fund • 25%
$1,000 to $2,000 • 25%
More than $2,000 • 25%
Less than $500 • 25%
$500 to $1,000 • 25%